医美近况交流

Summary of the Aesthetic Medicine Industry Conference Call Industry Overview - The aesthetic medicine industry is projected to see a revenue growth of 7% year-on-year in early 2024, with a customer traffic increase of approximately 10%, although the average transaction price is expected to decline by 3%-4% [2][3][21]. - Non-surgical light aesthetic projects account for 70% of the market, with photonic skin treatments making up 45% and non-invasive injection types 25% [2][5]. Key Insights and Arguments - Product Performance: - Recombinant collagen products, such as the Jingbo Weimei series, showed significant growth, with a 109% increase in January and an expected 60% in February [2][6]. - New products in the "童颜水光" (youthful water light) category and composite kinetic products also demonstrated strong growth [2][6]. - Pricing Trends: - Sales of the Weimei series are increasing, but prices are declining, particularly for the 4 mg model, which has seen a price drop of 30% [2][6]. - The average price decline is attributed to bundled sales strategies, leading to a 20%-30% decrease in average transaction prices [6][7]. - OEM Collaboration: - The rise of OEM collaboration is noted, with the group partnering with Jingbo to customize 8 mg products, reducing procurement costs and allowing flexible pricing strategies [2][8]. - The procurement cost for customized products is approximately 700 to 800 yuan, with a retail price set between 8,800 and 8,900 yuan [7][8]. - Market Dynamics: - The market is seeing a shift with pharmaceutical companies entering the aesthetic medicine field, leveraging their R&D and branding advantages, but facing challenges in adapting to the fast-changing market and consumer needs [4][15][16]. Additional Important Insights - Consumer Behavior: - Customer traffic during the Spring Festival showed a significant increase, particularly in first-tier cities, with some hospitals reporting appointment rates reaching 100% post-holiday [3][4]. - Product Innovations: - New products in the youthful water light category are being introduced with lower concentrations to make them more affordable, thus expanding the consumer base [9][10]. - Future Trends: - The aesthetic medicine industry is expected to maintain a growth rate of 8%-10% in 2026, driven by the introduction of new technologies and products, despite ongoing regulatory scrutiny [21]. - Sales Team Effectiveness: - Companies like Jinbo have developed strong sales teams that maintain good relationships with institutions and media, enhancing their competitive edge [17]. - Emerging Products: - The introduction of PDRN materials is anticipated to create a market potential of around 5 billion yuan, with several companies, including Lepu, working towards obtaining necessary certifications [20][21]. This summary encapsulates the key points discussed in the conference call regarding the aesthetic medicine industry, highlighting growth trends, pricing strategies, and market dynamics.